

ERRATUM

Open Access



Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival

Sigurd M. Hald^{1*}, Yury Kiselev^{3,6}, Samer Al-Saad^{3,5}, Elin Richardsen^{3,5}, Charles Johannessen³, Marte Eilertsen¹, Thomas K. Kilvaer², Khalid Al-Shibli^{3,4}, Sigve Andersen^{1,2}, Lill-Tove Busund^{3,5}, Roy M. Bremnes^{1,2} and Tom Donnem^{1,2}

Erratum

After publication of the original article [1], the author noticed that there are some error with Table 2 and Table 3. Please see the correct Tables below. We apologize for any inconvenience caused.

Author details

¹Department of Clinical Medicine, UiT The Arctic University of Norway, 9037 Tromsø, Norway. ²Department of Oncology, University Hospital of North Norway, Tromsø, Norway. ³Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway. ⁴Department of Pathology, Nordland Hospital, Bodo, Norway. ⁵Department of Clinical Pathology, UniversityHospital of North Norway, Tromsø, Norway. ⁶Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway.

Received: 14 November 2016 Accepted: 14 November 2016

Published online: 24 November 2016

References

1. Hald SM, et al. Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. *BMC Cancer*. 2015;15:441. doi:10.1186/s12885-015-1446-z.

* Correspondence: sigurd.hald@uit.no

¹Department of Clinical Medicine, UiT The Arctic University of Norway, 9037 Tromsø, Norway



Table 2 CXCL16 and CXCR6 expression as predictors of disease-specific survival in 335 NSCLC patients

Characteristics	Patients, N (%)	Median survival (months)	5-year survival (%)	P
CXCL16				
Cancer cells				.080
High	48 (14)	NR	67	
Low	227 (68)	98	56	
Missing	60 (18)			
Stromal cells				.016
High	258 (77)	189	62	
Low	43 (13)	57	48	
Missing	34 (10)			
CXCR6				
Cancer cells				.093
High	41 (12)	190	73	
Low	245 (73)	122	55	
Missing	49 (15)			
CXCL16				
Cancer cells + stromal cells combined				.016
High/High	43 (13)	NR	71	
High/Low	182 (54)	190	58	
Low/Low	41 (12)	47	48	
Missing	69 (21)			

NR, not reached; NSCLC, non-small cell lung cancer. Bold values indicate $p < 0.05$

Table 3 Results of multivariate Cox regression analyses for clinicopathological factors and CXCL16 in stromal cells (model 1) and co-expression of CXCL16 in cancer and stromal cells (model 2*)

Factor	HR	CI 95%	P
T-status			
T1	1.00		<0.001[†]
T2	1.60	(0.97-2.64)	0.065
T3	3.80	(2.13-6.77)	<0.001
N-status			
N0	1.00		<0.001[†]
N1	2.01	(1.30-3.11)	0.002
N2	3.08	(1.74-5.44)	<0.001
Differentiation			
Well	1.00		0.009[†]
Moderate	1.17	(0.63-2.20)	0.618
Poor	2.08	(1.12-3.85)	0.020
Performance status			
ECOG 0	1.00		0.040[†]
ECOG 1	1.52	(1.02-2.26)	0.040
ECOG 2	2.15	(0.94-4.91)	0.069
Vascular infiltration			
No	1.00		0.046
Yes	1.70	(1.01-2.87)	<0.001[†]
Histology			
Squamous carcinoma	1.00		<0.001
Adenocarcinoma	2.23	(1.48-3.35)	<0.001
Large cell carcinoma	0.80	(0.39-1.66)	0.555
CXC16 stromal cells			
Low	1		0.011
High	0.55	(0.35-0.87)	0.011
CXCL16 cancer and stromal cells*			
Low/Low	1.00		0.031[†]
Low/High + High/Low	0.57	(0.35-0.93)	0.023
High/High	0.42	(0.20-0.88)	0.022

[†]Overall significance as prognostic marker. HR, Hazard ratio. Bold values indicate $p < 0.05$